

SUBJECT INDEX

- Acamprosate, 669
 Acetaminophen, 189
 Acetylcholine (ACh), 23, 529, 637, 841
 ACh level, 99
 Acquisition, 211
 Active avoidance, 445, 837
 Activity, 581, 587
 Acute, 409
 Acute exercise, 773
 Added point loss, 139
 Addiction, 219
 Adrenalectomy, 599
 Adverse side effects, 567
 Aging, 611
 Agonist, 219
 Alarm cries, 551
 Alarm substance, 599
 Albuterol, 483
 Alcohol, 49, 105, 127, 133, 355, 587, 795
 Alcohol intake, 105
 Alcohol-related birth defects, 587
 Alcohol sensitivity, 795
 N-Allylnormetazocine, 215
 α_2 -Adrenergic receptors, 267
 α_2 -Receptor localization, 267
 α_2 -Receptor subtypes, 267
 α_{2A} , 267
 α_{2B} , 267
 Alphaxalone, 399
 Alprazolam, 425
 Amnesia, 715
 Amnesic agents, 761
 Amphetamine, 29, 203, 259, 309, 837
d-Amphetamine, 283, 391, 859
 Amygdala, 109, 115, 121, 127
 Analgesia, 53, 65, 153, 449, 665
 Androgen-dependent behavior, 195
 Angiotensin converting enzyme inhibitor, 105
 Angiotensin II, 105
 Angiotensin II-induced drinking, 183
 Antagonism, 245, 529
 Antagonist, 219
 Anticonvulsant, 109, 115, 121, 127, 789
 Antihypertensive agents, 567
 Antinociception, 53, 65, 371, 429
 Antipredator defense, 551
 Antistereotypic activity, 665
 Antitussive mixture, 783
 Anxiety, 551, 643, 683, 719
 Anxiolytic, 13, 405, 475, 573
 Anxiolytic effect, 425
 Apomorphine, 171, 177, 511
 Arginine vasopressin, 409
 Aromatization, 733
 Atipamezole, 611
 Atropine, 377
 Attention, 195
 Autoreceptor, 841
 Avoidance behavior, 145
 Avoidance schedule, 139
 Azaprophen, 377
 Baboons, 567
 Baclofen, 651, 695
 Barbiturates, 355
 Basal ganglia, 547
 Behavior, 219, 321, 461, 719
 Behavioral CRs, 239
 Behavioral effects, 377
 Behavioral satiety sequence, 801
 Behavioral sensitization, 841
 Behavioral tolerance, 121, 127, 133
 Benactyzine, 377
 Benzodiazepine inverse agonist, 455
 Benzodiazepine receptor ligands, 859
 Benzodiazepines, 355, 405, 461, 475, 529, 719
 β_2 adrenoreceptors, 483
 Bicuculline, 727
 Blood-brain barrier, 255
 Blood glucose, 295
 Blood pressure, 567
 BMX-14802, 29, 215
 Bone, 289
 Brain, 539
 Brain 3 H-2-deoxyglucose uptake, 295
 Brain glucose, 295
 Brain lesions, 727
 Brain self-stimulation, 391
 Brain-stimulation reward, 755
 Buspirone, 573
 Caffeine, 659, 783
 Calcium channel blocking agents, 567
 Calcium uptake, 695
 Cannabinoids, 469
 Carbamazepine, 109, 115, 121, 813
 Carbon monoxide, 749
 Catalepsy, 301, 547
 Catecholamines, 195, 329, 733, 739
 Cathinone, 37
 Central neurotransmission, 445
 Central receptors, 461
 Cerebellum, 761
 CGS 10746B, 37, 807
 Chemical and electric seizures, 99
 Chick, 761
 Chickens, 349
 Chlordiazepoxide, 475, 529, 643
 Chlorpheniramine, 783
 1-(*m*-Chlorophenyl)biguanide, 361
m-Chlorophenylpiperazine, 621
 Chlorpromazine, 13
 Choice, 817
 Choice measures, 825
 Cholecystokinin, 83
 Cholinergic, 23, 547, 625
 Cholinergic function, 433
 Cholinergic systems and memory, 715
 Cholinesterase in RBC and tissues, 773
 Cholinesterase inhibitor, 251
 Chronic, 409
 Chronic ethanol, 275
 Chronic intoxication, 49
 Cigarette smoke, 655
 Cigarette smoking, 749
cis-Flupenthixol, 489
 Classical conditioning, 239
 Clonazepam, 115
 Clonidine, 153, 519
 Clozapine, 29
 Cobalt epilepsy, 813
 Cocaine binding, 227
 Cocaine extinction responding, 415
 Cocaine methiodide, 851
 Cocaine, 219, 227, 283, 365, 377, 415, 497, 519, 643, 659, 837, 841, 851
 Cocaine-maintained responding, 415
 Codeine, 349
 Cognition, 159
 Cold exposure, 795
 Conditioned avoidance response, 29
 Conditioned drug effects, 239
 Conditioned flavor aversions, 239
 Conditioned food aversions, 239
 Conditioned place preference, 817, 825
 Conditioned taste aversion, 43, 239, 245, 455, 559
 Conditioned withdrawal, 543
 Conditioning, 13
 Conflict, 399
 Conflict behavior, 651
 Conspecific odors, 581
 Consummatory acts, 251
 Contingent tolerance, 121, 127, 133
 Continuous reinforcement, 309
 Convulsions, 109, 115, 121, 127, 133, 159, 599
 Copulation, 133
 Cortex, 317, 675
 Corticosterone, 317, 643, 795
 Corticotropin releasing factor, 399
 Cotinine, 701
 CQ 32-084, 683
 Cross tolerance, 115, 127, 355
 Cue learning, 529
 Cumulative dosing, 83, 365
 Curiosity, 625
 CY 208-243, 511
 D₁ dopamine receptors, 235
 D₁ receptors, 321, 343
 D₂ agonist, 65
 D₂ autoreceptors, 683
 D₂ receptors, 259, 343, 841
d-Amphetamine, 283, 391, 859
 DADL ([D-Ala², D-Leu⁵]enkephalin), 171
 Defensive withdrawal, 643
 Delayed spontaneous alternation response, 573
 Delta-amino-*n*-valeric acid, 651
 2-Deoxy-D-glucose, 371
 Dependence, 49
 Depression, 23
 [Des-Gly⁹,d(CH₂)₅¹,O-Et-Tyr²,Val⁴,Arg⁸]-vasopressin, 409
 Detection threshold, 391
 Development, 69, 469
 Dextromethorphan, 215
 Diabetes, 483
 Diazepam, 1, 13, 109, 121, 159, 461, 573, 695, 859
 Diazepam withdrawal, 695

- Differential conditioning, 333
 Differentiation, 69
 Dihydrocodeine, 783
 Dipsogenic agent, 183
 Discriminative stimulus effects, 377
 Discriminative stimulus properties, 391
 Ditolyguanidine, 215
 DN-2327, 573
 DOCA-salt hypertension, 567
 DOI, 519
 Domestic fowl, 349
 Domoic acid, 211
 DOPAC, 469
 Dopamine, 37, 57, 75, 177, 231, 343, 469, 489, 501, 511, 607, 643, 675, 683, 807, 841
 Dopamine autoreceptors, 227
 Dopamine D₁ antagonist, 507
 Dopamine metabolism, 301
 Dopamine receptors, 343
 DPLPE ([D-Pen², L-Pen⁵]enkephalin), 171
 Drinking, 847
 Drug dependence, 219
 Drug discrimination, 43, 165, 245, 321, 361, 783, 789
 Drug discrimination learning, 245
 Drug interaction, 83, 405, 659
 Drug kinetics, 489
 Drug reinforcement, 559, 825
 Drug tolerance, 133
 DSP-4, 195
- ECoG, 813
 Edema, 53
 EEDQ, 321
 Electrical resistance, 855
 Electroconvulsive shock, 663
 Elevated plus-maze, 643
 Elevated plus-maze test for anxiety, 91
 Eltoprazine, 801
 Eltoprazine hydrochloride (DU 28853), 581
 Emesis, 215
 Endorphins, 559
 Endurance-trained exercise, 773
 Enhancement of memory, 295
 Enrichment, 689
 Entorhinal cortex, 767
 Estrogen, 255
 Estrous, 153, 719
 Ethanol, 127, 133, 189, 263, 409, 455, 587, 663, 669, 689
 Ethanol intake, 385, 847
 Ethyl acetate, 79
 Experimental hypocholinergic model, 433
 Exploration, 625
 Exploratory behavior, 91
 Extinction, 847
 Extrahypothalamic, 329, 733
- Fixed-interval schedules, 377
 Fixed-ratio schedule, 83
 Flinders Sensitive Line, 23
 Fluid exchange, 183
 Flumazenil, 529
cis-Flupenthixol, 489
 Follicle stimulating hormone, 255
 Food intake, 7, 385
 Food-maintained responding, 415
 Foot-shock, 317
 Four plates test, 405
 FR/DRL schedule, 251
 Frontal cortex, 637
- GABA, 1, 49, 405, 501, 603, 651
 GABA levels, 99, 669
 GABA-T inhibitors, 603
 GABA_A receptors, 767
 Gender differences, 153
 Generalization, 43
 Genetic model, 795
 Gerbils, 231, 539
 Glucose, 65
 Glucose + saccharin-maintained responding, 415
 L- α -Glycerylphosphorylcholine, 445
 Glycine, 263
 Gonadectomy, 153
 Grooming, 385, 683
 Growth hormone, 795
 Gulls, 289
- H₂ receptor, 371
 [³H]-5-HT release, 695
³H-GABA uptake, 669
 Haloperidol, 13, 29, 177, 215, 301, 547
 Haloperidol decanoate, 13
 Hamsters, 543
 Hemispheric asymmetry, 761
 n-Hexane, 79
 Hippocampus, 211
 Histamine, 371
 Histamine-receptor, 317
 Homotaurine, 49
 Hot-plate, 449
 5-HT, 53, 91
 5-HT antagonists, 53
 5-HT receptors, 53, 429, 621
 5-HT uptake inhibitors, 801
 5-HT₁ receptors, 801
 5-HT_{1A}, 5-HT_{1B}, and 5-HT_{1C} receptors, 519
 5-HT₂ antagonist, 241
 5-HT₃, 361
 5-HT₃ antagonists, 659
 5-HT₃ receptors, 807, 847
 Human, 139
 HVA, 547
 HVS, PA, and WM performance, 611
 Hydrochlorothiazide, 567
 6-Hydroxydopamine, 343, 621
 Hyperactivity, 501, 603
 Hyperalgesia, 349
 Hyperglycemia, 65
 Hyperhydration, 183
 Hyperphagia, 371
 Hypoalgesia, 349
- Ibotenic acid, 607
 ICS 205-903, 37
 ICS 205-930, 361, 519
 Idazoxan, 267, 707
 IMHV, 761
- Imipramine, 599
 Immobility, 425, 507
 Inclined plane, 13
 Individual differences, 203
 Inferior colliculus, 727
 Inflammation, 53
 Ingestive behavior, 483
 Intake, 689
 Interactions, 13
 Intermediate-term memory, 761
 Intracerebral microinjection, 727
 Intracerebroventricular, 409
 Intraventricular, 329, 733
 Investigatory behavior, 625
 Ischemia, 231
 Isradipine, 37, 497, 807
- Ketanserin, 53
 Ketocyclazocine, 7
 Kindling, 109, 115, 121, 127
- L- α -Glycerylphosphorylcholine, 445
 Latency, 817, 825
 Lead, 289
 Learning, 211, 587, 625
 Learning and memory, 445, 573
 Lever release, 29
 LHRH agonist, 665
 LHRH antagonist, 665
 Lidocaine, 851
 Limited access procedure, 385
 Lisuride, 683
 Lithium, 239
 Liver, 289
 Locomotion, 91, 227, 301, 607
 Locomotor activity, 171, 203, 251, 365, 377, 391, 655
 Long-term memory, 761
 Lorazepam, 659, 795
 LPO, 761
 LS and SS mice, 275
 Luteinizing hormone, 255, 795
 Luteinizing hormone-releasing hormone, 255, 665
 LY-171555, 177
- 1-(*m*-Chlorophenyl)biguanide, 361
m-Chlorophenylpiperazine, 621
 Magnesium chloride, 415
 Magnesium-deficient diet, 415
 Male sexual behavior, 511, 739
 Masculinization, 329
 Matching-to-sample, 283
 mCPBG, 519
 MDA, 333
 MDL 72222, 37
 Mecamylamine, 755
 Median raphe nucleus, 501
 Melatonin, 405
 Memory, 1, 625, 761, 851
 Memory consolidation, 837
 Memory modulation, 837
 Memory retrieval, 145
 Methamphetamine, 783
 Methylephedrine, 783
 2-Methylserotonin, 361
 Methysergide, 53
 Metoclopramide, 177
 Mice, 171, 211, 301, 365, 429, 851, 855
 Mifepristone, 69
 Milacimide, 263
 Minaprine, 715

- Modified forced-swim test, 425
 Monoamine levels, 655
 Monoamines, 231
 Morphine, 83, 245, 449, 497, 543, 551, 615, 727, 825
 Morris water maze, 211, 529
 Motor behavior, 75, 567, 707
 Mouse striatum, 227
 Moving belt, 409
 Multitrial, 715
 Muscimol, 49, 501
 Mussel toxin, 211
 Myorelaxant, 13

 N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide (DM-9384), 231
 N-Allylnormetazocine, 215
 n-Hexane, 79
 Naloxone, 245, 349, 475, 543, 755
 Naloxone-precipitated withdrawal, 543
 Naltrexone, 559
 Naturalistic environment, 701
 Neonatal, 69, 329
 Neostriatum, 675
 Nerve agents, 159
 Neuroexcitant amino acid, 211
 Neuroexcitotoxin, 211
 Neuromotor development, 587
 Neurotensin, 385
 Neurotoxin, 211
 Neurotransmitter system preceptors, 539
 Nicotine, 23, 57, 139, 219, 701, 749, 755, 807
 Nicotine abstinence, 139
 Nictitating membrane response, 333
 Nimodipine, 497
 Nitrous oxide, 429
 NMDA receptors, 263, 767
 Nociception, 53
 Nomifensine, 391
 Nonhuman primates, 567
 Noradrenaline, 231
 Noradrenergic system, 739
 Norepinephrine, 195, 675
 Novel odors, 581
 Novelty, 203
 Nucleus accumbens, 57, 177, 203, 501
 Nucleus basalis, 637
 Nucleus basalis magnocellularis, 445

 Odansetron, 53
 Oestrous, 719
 8-OH-DPAT, 519
 Olfactory preference, 581
 One-way active avoidance, 851
 Ontogeny, 621
 Open field, 733
 Open-field behavior, 675
 Operant behavior, 251
 Opiate antagonists, 43, 559
 Opiate withdrawal, 543
 Opiates, 349, 559
 Opioid, 219, 349
 Opioid receptor, 65
 Oral dyskinesia, 621
 Organic solvents, 79
 Organophosphate, 159
 Oxytocin, 7

 P and NP rats, 105
 Pain, 53, 349
 Palatability, 559

 Para-aminoclonidine, 267
 Para-ethoxyamphetamine, 165
 Para-methoxyamphetamine, 165
 Paracetamol, 189
 Paroxetine, 801
 Partial reinforcement, 309
 Passive avoidance, 445, 573
 Passive avoidance tests, 715
 Pattern recognition, 707
 Paw pad, 855
 Penile erection, 511
 Pentobarbital, 127, 283
 Periaqueductal gray, 727
 Peripheral type receptors, 461
 Phencyclidine, 83, 283, 603
 Phenobarbital, 115
 Phlorizin, 295
 Phystostigmine, 529, 773
 Pigeons, 83, 283
 Pilocarpine, 153
 Pimozide, 13, 301, 489
 Place conditioning, 559, 817, 825, 859
 Place learning, 529
 Place task, 211
 Play, 817
 Plus maze, 13, 399
 Posttraining, 837
 Posttraining memory processing, 767
 (+)-3-PPP, 215
 Prefrontal cortex, 607
 Prepregnancy, 587
 Primates, 511
 Proactive interference, 283
 Progesterone, 69, 255
 Progressive degenerative dementia, 433
 Prolactin, 795
 Prostaglandin inhibitors, 189
 Psychopharmacology, 239
 Puff-by-puff analysis, 701
 Pulmonary alcoholization, 669
 Pyridostigmine, 251

 Q-ICS 205-930, 361
 Quinelorane, 511
 Quinpirole, 65

 Rabbit, 333
 Radioimmunoassay, 719
 Rapid tolerance, 355
 Rate of decarbamylation, 773
 Rats, 23, 37, 49, 53, 99, 109, 115, 121, 127, 133, 153, 203, 241, 317, 355, 371, 377, 409, 415, 461, 475, 507, 511, 529, 539, 573, 587, 607, 655, 675, 707, 783, 801, 807, 813, 817, 825, 837
Rattus norvegicus, 625
 Rauwolscine, 267
 Rearing, 655
 Receptor autoradiography, 539
 Red nucleus lesions, 99
 Reflex modification, 333
 Regulation, 219
 Reinforcement, 165, 219, 489
 Remoxipride, 259
 Renin-angiotensin system, 105
 Renovascular hypertension, 567
 Resistance to extinction, 309
 Respiration, 349
 Resting, 385
 Restraint stress, 449
 Restricted access, 847
 Reward, 489, 859

 Rhesus monkeys, 159, 235, 511
 Ritanserin, 241
 Ro 15-1788, 859
 Ro 15-4513, 455
 Ro 16-6028, 859
 (R/S)-4-VinylGABA, 603
 RU 486, 69

 (S)-4-AllenylGABA, 603
 SCH 23390, 177, 321, 507
 SCH 39166, 235
 Scopolamine, 529, 625, 715, 855
 Seizure, 109, 115, 121, 127, 263, 365, 663
 Self-administration, 165, 219, 259, 415, 615, 789
 Self-administration by naive mice, 497
 Self-stimulation, 489, 755
 Sensitization, 203, 275, 365
 Septum, 675
 Serial probe recognition (SPR), 159
 Serotonin, 53, 231, 241, 329, 501, 643, 675, 733, 789
 Sertraline, 789
 Sex differences, 551
 Sexual behavior, 69, 91, 133, 329, 733
 Sexual behavior and orientation, 91
 Sexual differentiation, 91, 733
 Sexual hormones, 329
 Shock-induced fighting, 49
 Short-term memory, 761
 Sigma site, 215
 Single cigarette, 701
 SK&F 38393, 177, 321
 SK&F 83566, 507
 Sleep, 241
 Smoking, 701
 Social reinforcement, 817
 Sodium valproate, 109, 121
 Solvents and convulsions, 79
 Soman, 159
 SP(1-7), 75
 Spatial discrimination, 817
 Spatial learning, 1, 637
 Spatial navigation, 211
 SQ 29,852, 105
 Stereotypic behavior, 343
 Stereotypy, 29
 Steroids, 399
 Stimulus properties of drugs, 37, 807
 Straw-climbing behavior, 425
 Straw suspension, 425
 Stress, 317, 399, 587, 599, 607, 615, 663
 Striatum, 203
 Subcutaneous, 409
 Submissive odors, 581
 Substance P, 75
 Substantia nigra, 75
 Successive discrimination, 475
 Sulpiride, 29, 301
 Supersensitivity, 343, 519
 Supersensitization, 621
 Sustained release, 219
 Swim, 607

 Tail-flick, 449
 Tail suspension test, 405
 Taste conditioning, 559
 Taste reactivity, 559
 Taste reactivity test, 239
 Testosterone, 255
 TFMP, 519
 THA, 637

- Thalamus, 675
Thermal nociception, 349
Thermoregulation, 23
Thiazide diuretics, 567
Thioridazine, 13
Thyrotropin, 795
Thyroxine, 145
Tissue deposition, 289
Titration schedule, 283
Tobacco abstinence, 139
Tobacco administration, 139
Tobacco smoke exposure reduction, 749
Tolerance, 109, 115, 121, 127, 275, 409
Toluene, 79
Toxin, 547
TRH, 145
Triiodothyronine, 145
Trimethadione, 115
Turning, 177
Tyrosine hydroxylase, 469
Ultrasonic vocalization, 551
Up-regulation, 235
Vaginal opening, 69
Valproic acid, 109, 121
Vasopressin, 7, 409
Ventral mesencephalon, 675
Verapamil, 567
Vigabatrin, 603
Visual discrimination, 251
Vocal control system, 195
Vocalizations, 739
Waking, 241
Water, 817
Water intake, 251, 385, 847
Wet-dog shakes, 99
Wild running, 727
Withdrawal, 49
X-maze, 683
Yohimbine, 267, 707
Zacopride, 847
Zolantidine, 371

AUTHOR INDEX

- Abel, E. L., 599
 Airaksinen, M. M., 701
 Alburges, M. E., 267
 Allen, R. P., 567
 Alvares, K., 615
 Ambrogio Lorenzini, C., 715
 Amit, Z., 259
 Ando, K., 783
 Andrews, N., 695
 Araki, T., 539
 Araki, Y., 655
 Arolfo, M. P., 1
- Bagri, A., 727
 Baldi, E., 715
 Banks, W. A., 255
 Barclay, S. R., 195, 739
 Barfield, R. J., 69
 Barrera, C. M., 255
 Bennett, E. L., 761
 Bennett, R. H., 139
 Bilitzke, P. J., 599
 Billing, A. E., 719
 Bitar, M. S., 483
 Blanchard, D. C., 551
 Blanchard, R. J., 551
 Blengio, M., 317
 Bodnar, R. J., 153, 371
 Bolioli, B., 547
 Booth, R. A., 433
 Bose, R., 211
 Bowes, M. P., 707
 Brigham, J., 749
 Brioni, J. D., 1
 Britton, K. T., 399
 Bucherelli, C., 715
 Bueno, L., 461
 Burger, J., 289
 Bylund, D. B., 267
- Cade, J. R., 183
 Calcagnetti, D. J., 449
 Carey, M. P., 719
 Castelló, M. E., 547
 Castresana, A., 49
 Castro, C. A., 159
 Chang, A. S., 433
 Cheng, M.-F., 739
 Cherek, D. R., 139
 Chiang, P. K., 377
 Chipkin, R. E., 235
 Christensen, B. K., 133
 Ciancone, M. T., 29
 Coen, K. M., 165
 Colasanti, B. K., 813
 Consolo, S., 99
 Corrigall, W. A., 165
 Cotton, D. B., 599
 Cottrell, G. A., 507
 Cottrill, K. L., 295
 Craig, C. R., 813
 Crowder, W. F., 817, 825
- Da Silva, R. C., 767
 Dajas, F., 547
 Daoust, M., 669
- Darmani, N. A., 519
 De Miguel, R., 469
 Dell'anna, E., 231
 Desouza, E. B., 483
 Destrade, C., 177
 Deutsch, S. I., 263, 663
 Dewitte, P., 669
 Di Scala, G., 727, 859
 Dilsaver, S. C., 23
 Dodson, D. L., 625
 Domanague, K. R., 455
 Drago, F., 445
 Dube, S. N., 773
 Duffy, R. A., 235
 Dukat, M., 361
 Dunn, A. J., 643
 Durbin, P., 669
- Emmanouilidis, E., 49
 Erwin, V. G., 275
- Farabollini, F., 91
 Fargeas, M. J., 461
 Fasold, M. B., 255
 Felch, L. J., 749
 Feldon, J., 309
 Fernández-Ruiz, J. J., 469
 Ferrari, F., 683
 Ferrario, P., 99
 Ferreira, M. B. C., 767
 Ferretti, C., 317
 File, S. E., 695
 Fillmore, M. T., 13
 Finger, A. V., 159
 Franklin, K. B. J., 489
 Fratta, W., 497
 Fregly, M. J., 183
 Fry, J. P., 719
 Fujiwara, H., 301
 Fukuda, N., 573
 Fung, Y. K., 57
- Gamzu, E. R., 145
 Genovese, R. F., 377
 George, F. R., 189
 Gessa, G. L., 497
 Geter, B., 43
 Gewiss, M., 669
 Ghi, P., 317
 Gibson, J. E. M., 689
 Gifford, A. N., 841
 Giordano, J., 53
 Giuliani, D., 683
 Glavin, G. B., 211
 Glennon, R. A., 361
 Glesson, R. A., 519
 Glin, L., 241
 Gochfeld, M., 289
 Goeders, N. E., 643
 Gold, P. E., 295
 Gornita, Y., 655
 Gong, L., 621
 Gonzalez, I., 91
 González, M. I., 329, 733
 Gorman, A. L., 643
 Gormezano, I., 333
- Gottesmann, C., 241
 Grauffel, C., 603
 Grunberg, N. E., 615
 Grupp, L. A., 105
 Guardiola-Lemaître, B., 405
 Gui-Hua, C., 321
 Guidi, G., 445
 Gulati, K., 7
- Hall, J. L., 295
 Hall, M. E., 75
 Haracz, J. L., 29
 Harding, C. F., 195
 Hauger, R., 399
 Heidbreder, C., 669
 Henningfield, J. E., 189
 Hernández, M. L., 469
 Hicks, L. H., 455
 Hienz, R. D., 567
 Holtzman, S. G., 449
 Hooks, M. S., 203
 Hopper, D. L., 707
 Hough, L. B., 371
 Hudda, M. M., 115
 Hudzik, T. J., 215
 Hughes, R. A., 349
 Hunt, M. A. E., 267
 Huston, J. P., 675
 Huston-Lyons, D., 755
 Hutto, C. W., Jr., 817, 825
- Ishida, Y., 539
 Izquierdo, I., 767
- Janak, P. H., 837, 851
 Jaskiw, G. E., 607
 Jenden, D. J., 433
 Jensen, K., 239
 Johnson, K. M., 841
 Jones, B. C., 275
 Jones, C. H., 121
 Jones, G. H., 203
 June, H. L., 455
 June, P. L., 455
 Junien, J.-L., 659
 Justice, J. B., Jr., 203
- Kádár, T., 665
 Kalant, H., 355, 409
 Kameyama, T., 171
 Kaminska, G., 235
 Kantak, K. M., 415
 Kastin, A. J., 255
 Kato, H., 539
 Kautz, M. A., 43
 Kawashima, T., 855
 Keis, A. F., 483
 Kemble, E. D., 581
 Kernan, W. J., Jr., 707
 Khanna, J. M., 355
 Kiefel, J. M., 153
 Kim, C. K., 109, 115, 121, 127
 Kimball, K. A., 283
 Kirkpatrick-Steger, K., 333
 Klein, S. A., 189
 Kleinrok, Z., 99
- Knapp, D. J., 847
 Koch, J. E., 371
 Kogure, K., 539
 Kojima, H., 231
 Kolasa, K., 99
 Kolonen, S., 701
 Koob, G. F., 399
 Kornetsky, C., 755
 Korpi, E. R., 795
 Kostrzewa, R. M., 621
 Kulkosky, P. J., 385
 Kuzmin, A., 497
- Lammintausta, R., 611
 Larsen, T., 159
 Lau, Y.-S., 57
 Lauretz, S. D., 433
 Lauria, N., 445
 Lawley, S. I., 415
 Leduc, P. A., 625
 Legrand, E., 669
 Lénègre, A., 405
 Lepore, M., 489
 Leret, M. L., 329, 733
 Levin, E. D., 219
 Lewis, M. J., 455
 Lindqvist, E., 231
 Liu, J.-F., 409
 Liu, W.-F., 251
 Lodge, B. A., 165
 Lukacs, L. G., 263
 Lummis, G. H., 455
 Luthman, J., 231
- MacNeil, D. A., 145
 Mana, M. J., 109, 121
 Mandel, R. J., 343
 Männistö, P. T., 795
 Martellotta, M. C., 497
 Martin, B. R., 519
 Martinez, J. A., 461
 Martinez, J. L., Jr., 837, 851
 Mastropaolo, J., 263, 663
 Mauceri, F., 445
 McGuirk, J., 801
 McLeod, S., 399
 McMaster, S. B., 159
 McNamara, R. K., 529
 McNaughton, N., 475
 McQuade, R. D., 235
 Medina, J. H., 767
 Meehan, S. M., 807
 Messier, C., 177
 Meyer, M. E., 507
 Michael, R. P., 391
 Mihic, S. J., 409
 Mrabet, O., 177
 Mueller, J. L., 429
 Mulven, R., 483
 Muscat, R., 801
- Nader, M. A., 789
 Nardo, L., 445
 Neill, D. B., 203
 Nespor, S. M., 615
 Nishimura, H., 425

- Norris, D. O., 263
 Novitzki, M. R., 263, 663
- O'Connor, D. A., 263
 O'Connor, T., 415
 Oberling, P., 859
 Oishi, R., 655
 Olson, L., 231
 Orikasa, S., 855
 Ostrem, J. L., 581
 Overstreet, D. H., 23
 Owusu, S. E., 483
- Parker, L. A., 239, 559
 Paul, D., 65
 Payan, C., 49
 Peck, J. A., 23
 Pelloni, F., 683
 Perry, B. D., 321
 Peters, R. H., 707
 Petrie, B. F., 211
 Pfaus, J. G., 133
 Pickworth, W. B., 189
 Pinel, J. P. J., 109, 115, 121, 127, 133
 Pinsky, C., 211
 Pires, M. L. N., 79
 Pleim, E. T., 69
 Poenaru, S., 49
 Pohorecky, L. A., 847
 Pomerantz, S. M., 511
 Porsolt, R. D., 405
 Portaleone, P., 317
 Pournaghash, S., 245
 Puustinen, P., 701
- Quock, R. M., 429
- Radcliffe, R. A., 275
 Ramos, J. A., 469
 Rampello, L., 445
 Ramus, S. J., 761
 Randall, P. K., 343
 Rawleigh, J. M., 581
- Ray, A., 7
 Rebec, G. V., 29
 Reilly, R. T., 295
 Reilly, S. M., 289
 Reith, M. E. A., 227
 Renner, M. J., 625
 Rennie, M., 559
 Rice, K. M., 433
 Riedel, C. A., 851
 Riekkinen, M., 611, 637
 Riekkinen, P., 611
 Riekkinen, P., Jr., 611, 637
 Riley, A. L., 43, 245
 Roane, D. S., 65
 Robertson, J. M., 165
 Roch, M., 433
 Rocha, B., 859
 Rockman, G. E., 689
 Rodgers, R. J., 551
 Rodríguez de Fonseca, F., 469
 Roese, N. R., 127
 Rose, J. E., 219
 Rosenzweig, M. R., 761
 Rouhani, S., 49
 Rowland, N. E., 183
 Ruggles, J. L., 13
 Russell, R. W., 433
- Saeki, K., 655
 Saito, M., 855
 Sandner, G., 727, 859
 Sandoval, S. L., 385
 Schaefer, G. J., 391
 Schally, A. V., 665
 Schechter, M. D., 37, 807
 Schnur, P., 543
 Schomburg, F. M., 53
 Schwarting, R. K. W., 675
 Seiler, N., 603
 Selmecci, G., 227
 Serrano, P. A., 761
 Shah, G., 355
 Shaham, Y., 615
- Sharma, K. K., 7
 Shephard, R. A., 651
 Shepherd, J. K., 551
 Shiotani, T., 231
 Shiotsuki, N., 79
 Shuto, K., 539
 Silhol, S., 241
 Silva-Filho, A. R., 79
 Sirviö, J., 611, 637
 Skelton, R. W., 529
 Smith, B. R., 259
 Smurthwaite, S. T., 43
 Solana, R. P., 159
 Somani, S. M., 773
 Soulairac, A., 49
 Standish, N. M., 211
 Stevenson, G. W., 245
 Stewart, J. M., 75
 Stitzer, M. L., 749
 Stone, W. S., 295
 Stwertka, S. A., 145
 Suemaru, K., 655
 Sufka, K. J., 53, 349
- Tachizawa, H., 231
 Tanaka, M., 425
 Tassoni, G., 715
 Taukulis, H. K., 13
 Telegdy, G., 665
 Terry, P., 365
 Thompson, D. M., 83
 Torres, F. K., 587
 Toyoshi, T., 171
 Tran, G., 49, 669
 Trifunovic, R., 501
 Tripp, G., 475
 Tuominen, K., 795
 Tuomisto, J., 701
 Turkkan, J. S., 567
- Ukai, M., 171
- Valerio, C., 445
 Van Hartesveldt, C., 507
- Vander Linden, S., 333
 Vanover, K. E., 789
 Verderese, A. G., 145
 Vincent, G. P., 145
- Wada, T., 573
 Wainwright, M., 543
 Wamsley, J. K., 267
 Wasserman, S. J., 415
 Waterman, S. A., 195
 Wedlock, P., 651
 Weinberger, D. R., 607
 Weinberger, S. B., 851
 Weiner, I., 309
 Weiner, J., 355
 Weinstein, M. A., 69
 Weiss, S. M., 551
 Wenger, G. R., 283
 Wettstein, J. G., 659
 White, I. M., 29
 Wilcox, R. E., 343
 Willner, P., 801
 Wilson, C. A., 91
 Wilson, K. M., 183
 Wilson, N. E., 651
 Winsauer, P. J., 83
 Wirtshafter, D., 501
 Witkin, J. M., 377
 Witkin, K. M., 377
 Wong, D. J., 115
 Woolverton, W. L., 321, 789
 Wu, P. H., 409
- Yanagita, T., 783
 Yang, X.-M., 643
 Young, R., 361
 Yung, A., 115
- Zecca, L., 99
 Zharkovsky, A., 695
 Zimmerberg, B., 587
 Zvartau, E., 497